Michelle Fladung has a three-year-old granddaughter. She looks forward to watching her go to her first day of kindergarten. She looks forward to a lot of future milestones for her granddaughter – milestones she plans to see in person. As Michelle says, “I have a lot to live for.”
“A lot to live for” is a commonly used phrase in our culture. Yet, it doesn’t seem overused. But then again, could this exact phrase ever actually be overused?
Overused or not, when this phrase comes out of the mouth of a stage 4 ovarian cancer survivor, it comes out in bold, italicized, underlined font. It is strong.
2014 was not a good year for Michelle Fladung. She lost her mother on October 9, 2014, had surgery to repair a hernia on October 13, 2014 and, in the process of repairing the hernia, doctors discovered she had stage 4 ovarian cancer. Yet, in retrospect, she does make note of two huge blessings:
- Michelle is extremely thankful that her beloved mother never knew that she had cancer.
- Had it not been for the hernia, the ovarian cancer discovery would likely have been made way too late.
They say ovarian cancer is the “silent killer.” It presents very few detectable symptoms until, too often, it is too late. For Michelle, it was almost too late. Her type of ovarian cancer has a 17% 5-year survival rate. She is in year 4. She feels better than she has at any time over the past 3 years. She is strong.
Michelle attributes her current good health to cancer research. Over the past three years, she has been a part of two clinical trials, leading to this most recent round of treatment – a cutting edge drug that is providing a quality of life Michelle hasn’t experienced since 2014. In fact, it is so cutting edge, Michelle is the first patient at Duke Cancer Center to receive this treatment outside of a clinical trial.
The term “clinical trial” sounds institutionalized, but in real life, the words “clinical trial” translate into “hope.”
Lots of hope.
Hope for the future, a better future. Hope for more days and time to make memories with a granddaughter who will one day understand the strength of her grandmother.
As thanksgiving approaches, we think about all the things we are thankful for. It turns out very few of them are “things.” Most of them are people. Some of them are ideals. We are thankful for the hope that research can provide, but most of all, we are thankful for the people that research can give us more time to enjoy, people like Michelle.
To donate to the Kay Yow Cancer Fund, click here.